|
Patent landscape, scope, and claims: |
Executive summary
- US Patent 10,351,517 claims methods of increasing wakefulness/alertness by administering a compound of Formula (I) (or a pharmaceutically acceptable salt/ester) to subjects with specified CNS or sleep-related conditions (including narcolepsy, sleep apnea, hypersomnia, sleep deficiency) and also broader cohorts such as shift workers and those taking sedating drugs.
- The claim set is broad on (i) indication scope, (ii) regimen context (shift work/sedating drugs), (iii) dose windows, and (iv) form selection (racemate or specific enantiomeric compositions, including ≥90% and ≥98% predominance).
- Enforcement risk for generics is elevated because method claims cover use rather than only composition, and the compound is defined at a formula level, not by a single named structure.
- This patent is best treated as a use/indication protection layer over a defined chemical space; the practical scope hinges on (a) what Formula (I) concretely covers in the specification and (b) whether later products fall within the compound/formulation/enantiomer boundaries.
What is the scope of US Patent 10,351,517 claim 1 for increasing wakefulness?
Core scope in one line: claim 1 covers dosing a subject with a compound of Formula (I) (or acceptable salt/ester) where wakefulness/alertness is increased, and the subject has one of a wide set of CNS/sleep/behavioral/medical conditions or risk contexts.
Claim 1 structural elements (what must be proven)
-
Method purpose and functional result
- “A method of increasing wakefulness or alertness… thereby increasing wakefulness or alertness.”
- This creates a functional use limitation: the accused act must be a dosing regimen aimed at producing wakefulness/alertness.
-
Administration of “a compound of Formula (I)”
- The claim does not name a single compound; it defines a Markush-style chemical genus.
- Infringement turns on whether the accused active falls within the genus defined by:
- R: hydrogen; lower alkyl (C1–C8); halogen (F, Cl, Br, I); alkoxy (C1–C3); nitro; hydroxy; CF3; thioalkoxy (C1–C3).
- x: integer 1–3, with a proviso allowing R may be the same or different when x=2 or 3.
- R1 and R2: independently hydrogen, lower alkyl (C1–C8), aryl, arylalkyl, cycloalkyl (C3–C7); or
- alternatively R1 and R2 are joined to form a 5–7 membered heterocycle substituted with hydrogen/alkyl/aryl, where the ring has 1–2 nitrogen atoms and 0–1 oxygen atom, and the N atoms are not directly connected to each other or to the oxygen.
-
Subject selection limitation (broad, listing-based)
- The method is limited to subjects having:
- CNS pathologic abnormality, stroke, narcolepsy, idiopathic CNS hypersomnia, sleep deficiency, sleep apnea, obstructive sleep apnea, insufficient nocturnal sleep
- chronic pain, acute pain
- Parkinson’s disease
- urinary incontinence
- multiple sclerosis fatigue
- ADHD
- Alzheimer’s disorder
- bipolar disorder
- cardiac ischemia
- circadian pacemaker misalignment with the environment
- jet lag
- or alternatively the subject is doing shift work or taking sedating drugs
- The inclusion of “CNS pathologic abnormality” and the long list expands potential coverage beyond classical narcolepsy/circadian indications.
-
Salt/ester coverage
- Includes “pharmaceutically acceptable salt or ester thereof,” expanding reach to salt form variants and prodrugs/esters within the claimed genus.
How broad is the “Formula (I)” definition in practice?
- The claim is generic-by-structure. It is not limited to one specific drug molecule.
- However, the true breadth depends on the actual substitution pattern embodied in Formula (I) in the granted document (the claim text you supplied defines allowed substituents but does not provide the full scaffold). Without the scaffold, the “covered universe” cannot be mapped to named compounds with precision.
- What can be stated from the claim text alone:
- R variability (C1–C8 alkyl, C1–C3 alkoxy/thioalkoxy, halogens, CF3, hydroxy, nitro) supports multiple substitution embodiments.
- R1/R2 heterocycle option adds another breadth dimension via fused/joined substitution that permits heterocycles with constrained heteroatom patterning.
Does US 10,351,517 cover narcolepsy specifically or only broad alertness treatment?
Answer: It covers narcolepsy explicitly and also covers broader “wakefulness/alertness” use across multiple conditions.
Narcolepsy-specific dependent claims
- Claim 2: “wherein the subject has narcolepsy.”
- Claim 7: same dependency for claim 6 (enantiomeric version).
- These dependencies reinforce that narcolepsy is a direct, not merely incidental, protected use.
Broader subject categories also include narcolepsy
- Claim 1’s listing includes narcolepsy among many other conditions; therefore, even without claim 2, an asserted method for narcolepsy would still read on claim 1 if the accused regimen uses a Formula (I) compound and increases wakefulness/alertness.
What dosing ranges does US 10,351,517 claim, and do those ranges limit infringement?
Answer: The patent includes dose range dependent limitations (claims 3–4 and 12–13). Literal infringement is strongest when the accused regimen falls within the claimed windows, but claim 1 itself is not dose-limited.
Dependent dose limitations
For racemate/composition-agnostic claim 1:
- Claim 3: effective amount 0.01 mg/kg/dose to 300 mg/kg/dose
- Claim 4: effective amount 1 mg/day to 7000 mg/day
For enantiomer-focused claim 6:
- Claim 12: 0.01 mg/kg/dose to 300 mg/kg/dose
- Claim 13: 1 mg/day to 7000 mg/day
Does claim 1 require dosing within these ranges?
- No. Claim 1 requires an “effective amount” but does not numerically define the range.
- Numerically ranged dependents matter for:
- strength of literal infringement arguments
- claim construction disputes (efficacy and “effective amount” tied to dose)
How does the enantiomer version (claims 6–14) change infringement risk?
Answer: Claim 6 creates an additional, narrower use claim that targets specific stereochemical compositions, including substantial enantiomer predominance thresholds.
Claim 6’s stereochemistry limitation
- Administering:
- “an enantiomer of Formula (I) substantially free of other enantiomers”
- OR “an enantiomeric mixture wherein one enantiomer… predominates”
- The allowed compound is still within Formula (I) genus but constrained by enantiomeric purity/predominance.
Quantified predominance dependent claims
- Claim 8: predominates to ~90% or greater
- Claim 9: predominates to ~98% or greater
Specific enantiomer dependent claims
- Claim 10: (R) or (D) enantiomer
- Claim 11: (S) or (L) enantiomer
Oral route limitation
- Claim 14: administered orally (dependent on claim 6)
Practical read-across
- If a competitor sells a racemate (equal enantiomer distribution), claim 6 may not read if “predominates” or “substantially free” is not satisfied. But claim 1 is not stereospecific and thus can still be asserted if the racemate contains a Formula (I) compound within the genus.
- If a competitor sells a single-enantiomer product (especially ≥98% ee), claim 6 and its dependent stereochemical thresholds become higher-risk.
What route of administration is protected?
Answer: The independent claims do not specify route; dependent claim 5 and 14 cover oral administration.
- Claim 5: compound of claim 1 administered orally
- Claim 14: enantiomer of claim 6 administered orally
If an accused product is administered non-oral (e.g., transdermal, intranasal, injectable), claim 1 remains route-neutral while claim 5/14 would not.
What “subject conditions” are captured, and which ones expand beyond classic wakefulness disorders?
Answer: The listing includes conventional sleep disorders plus several comorbidity and neuro/psychiatric conditions that broaden licensing and litigation exposure.
Included conditions and cohorts (from claim text)
- Sleep/wake disorders: narcolepsy, idiopathic CNS hypersomnia, sleep deficiency, sleep apnea/obstructive sleep apnea, insufficient nocturnal sleep, circadian pacemaker misalignment, jet lag, shift work, sedating drugs.
- Neuro disorders and CNS: stroke, CNS pathologic abnormality, Parkinson’s disease, multiple sclerosis fatigue, Alzheimer’s disorder, ADHD, bipolar disorder.
- Pain: chronic pain, acute pain.
- Other physiological conditions: urinary incontinence, cardiac ischemia.
Impact on commercial freedom
- Marketing labels and off-label promotion matter. Because claim coverage is tied to “increasing wakefulness or alertness” and not solely to a formal FDA diagnosis, a product positioned for alertness in broader neurologic or psychiatric populations may face read-through arguments if the subject category matches the claim listing and the prescribing behavior targets alertness.
How strong is the patent estate logic for Formula (I) wakefulness methods?
Answer: As presented in your claim set, strength comes from:
- genus-level chemical definition (Formula I),
- broad indication listing (including shift work/sedating drugs),
- route/dose and stereochemical dependents that allow multiple claim tracks.
Strength drivers
- No single named compound requirement: Formula (I) genus reduces the ability to design around by using small scaffold changes unless they move outside the permitted R/R1/R2 pattern.
- Use-driven protection: Method-of-use claims can be asserted even when a generic composition is the same, depending on infringement proof tied to clinical use and labeling/promotion.
Potential weakness (within the claim text provided)
- The enforcement burden remains high because infringement of method claims requires proving:
- administration of a qualifying Formula (I) compound
- to a subject meeting the claim’s disease/cohort limitation
- with a regimen that increases wakefulness/alertness.
- These are factual questions that can be contested through evidence of labeling, physician intent, and actual use.
What generic entry risks exist for a method-of-use claim like this?
Answer: The most direct risk comes from Paragraph IV-style incentives if an ANDA (or other approval pathway) relies on a reference drug whose active falls within Formula (I) and whose marketed/used patient population aligns with the claim’s subject list.
Key infringement pathways
- Labeling-based: if the reference product’s label or proposed labeling is used to show the intended use matches “increasing wakefulness/alertness” for listed conditions.
- Evidence of actual use: for method-of-use claims, use can be established through prescribing patterns, trials, or promotional materials.
Design-around options typically used
- Stereochemical changes (if the competitor can avoid “substantially free” or “predominant” requirements) help only against claim 6/8/9/10/11, not claim 1.
- Chemical redesign can avoid the claim only by leaving the structural constraints of Formula (I) (R, x, R1/R2, and heterocycle pattern). The claim text you provided indicates many allowed substituents, which can limit viable design-around space.
How do claims 1 and 6 interact in a freedom-to-operate assessment?
Answer: They create two overlapping tracks:
- Track A (claim 1): any Formula (I) compound (salt/ester), race-inclusive.
- Track B (claim 6): enantiomeric predominance or stereopurity variants of Formula (I).
Overlaps that matter
- If an accused product is a single enantiomer but also within Formula (I), both tracks may be implicated (claim 1 plus claim 6).
- If an accused product is a racemate, claim 6 may fail stereochemistry-dependent limitations, but claim 1 remains.
What is the practical “claim scope” for salts and esters?
Answer: Claim text expands coverage beyond the free base/acid form.
- Any pharmaceutically acceptable salt or ester of a qualifying Formula (I) compound is within the method claims.
- That increases risk from:
- salt-form selection
- prodrug/ester prodrug strategies, if the ester/prodrug qualifies as a claimed “ester” and results in administration of the active encompassed by Formula (I) and claim definitions.
Key takeaways
- US 10,351,517 is a broad method-of-use patent covering administration of Formula (I) compounds (plus salts/esters) to increase wakefulness/alertness in a wide set of subject categories that includes narcolepsy, sleep apnea/hypersomnia, circadian misalignment, shift work, and sedating drug cohorts, plus broader neuro/psychiatric and pain conditions.
- Claim 1 is not limited by dose, route, or stereochemistry, making it the broadest infringement hook.
- Claims 3–4 and 12–13 add numerical dose ranges; claims 5 and 14 add oral route; and claims 6–11 add enantiomeric predominance and specific (R/D) or (S/L) limitations.
- Enantiomer targeting mainly affects claim 6 and its dependents, not claim 1.
- Commercial and litigation exposure should be mapped to:
- whether competitor actives fall within Formula (I) substitution and heterocycle constraints
- whether prescribing/labeling ties to the listed subject diseases/cohorts
- whether stereochemical composition meets ≥90% or ≥98% predominance thresholds (for claim 6/8/9).
FAQs
-
Does US 10,351,517 require a specific FDA-approved indication to infringe?
The claim is tied to patient “subject” conditions listed in the claim text and to the functional aim of increasing wakefulness/alertness, not explicitly to an FDA indication wording.
-
If a competitor’s product is a racemate, can it avoid claim 6?
Claim 6 requires an enantiomeric composition with predominance/substantially-free characteristics; a racemate may not satisfy those dependents, but claim 1 remains stereochemistry-neutral.
-
Can non-oral administration avoid the oral-dependent claims?
Dependent claims 5 and 14 require oral administration. Non-oral routes can avoid those dependents, while claim 1 can still read if its other elements are met.
-
How does the heterocycle option in Formula (I) affect design-around strategies?
It expands the genus to ring-joined R1/R2 alternatives with specified heteroatom constraints, making scaffold-level redesign harder unless it moves outside the allowed substitution/heteroatom pattern.
-
Do the claimed dose ranges limit claim 1 infringement?
No. Claim 1 uses “effective amount” without numeric limits; the numeric windows apply to dependent claims.
References
- US Patent 10,351,517 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
